Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Trial Profile

Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Febuxostat (Primary) ; Verinurad (Primary)
  • Indications Hyperuricaemia
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 01 Jun 2018 Status has been changed to recruiting.
    • 01 Jun 2018 Planned number of patients changed from 24 to 36.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top